≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Pediculosis and phthiriasis, including avohilmo

Endpoint Browser PheWeb

AB1_PEDICULOSIS_AND_PHTHIRIAASIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — B85
  • Hospital discharge: ICD-10 — B85
  • Hospital discharge: ICD-9 — 13[2-3]
  • Hospital discharge: ICD-8 — 13[2-3]
  • Hospital discharge: excluded ICD-9 — 1330A
  • Hospital discharge: excluded ICD-8 — 13[3-4]0
  • Cause of death: ICD-10 — B85
  • Cause of death: ICD-9 — 13[2-3]
  • Cause of death: ICD-8 — 13[2-3]
  • Cause of death: excluded ICD-9 — 1330A
  • Cause of death: excluded ICD-8 — 13[3-4]0

3 out of 7 registries used, show all original rules.

270

4. Check minimum number of events

None

270

5. Include endpoints

None

270

6. Filter based on genotype QC (FinnGen only)

247

Control definitions (FinnGen only)

Control exclude
AB1_PEDICULOSIS_ACARIASIS_OTHERINFEST

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF13

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 247 145 102
Unadjusted period prevalence (%) 0.05 0.05 0.05
Median age at first event (years) 34.95 39.25 28.83

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
270
Matched controls
2700
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
B85.0
ICD-10 Finland
Pediculosis due to Pediculus humanus capitis
+∞
166.4
142
*
B85.3
ICD-10 Finland
Phthiriasis
+∞
49.5
46
*
1322A
ICD-9 Finland
Pediculosis and phthirus infestation, Phthirus pubis [pubic louse]
+∞
21.1
20
*
13299
ICD-8 Finland
Pediculosis
+∞
19.0
18
*
S73
ICPC
Pediculosis/skin infestation other
56.6
18.2
21
*
P02CF01
ATC
ivermectin; oral
101.8
17.8
19
*
B85.2
ICD-10 Finland
Pediculosis, unspecified
+∞
11.5
11
*
L29
ICD-10 Finland
Pruritus
12.9
10.0
17
14
B85
ICD-10 Finland
Pediculosis and phthiriasis
+∞
9.4
9
*
N76.0
ICD-10 Finland
Acute vaginitis
3.2
9.4
41
144
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.4
9.0
75
369
Z11.3
ICD-10 Finland
Special screening examination for infections with a predominantly sexual mode of transmission
3.2
8.3
35
120
M54
ICD-10 Finland
Dorsalgia
2.5
7.4
52
235
Z71.8
ICD-10 Finland
Other specified counselling
2.0
7.1
117
744
R07.0
ICD-10 Finland
Pain in throat
2.9
6.6
32
119
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
3.7
6.3
20
57
13399
ICD-8 Finland
Acariasis, Other
+∞
6.3
6
*
B86
ICD-10 Finland
Scabies
5.6
6.3
17
32
T36
ICD-10 Finland
Poisoning by systemic antibiotics
3.3
6.0
23
74

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
hydrocortisone butyrate
D07AB02 [21602106]
5.9e-01
1.4e+00
—
—
2.8e+00
1.7e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.76%
cases:15.44%
controls:4.83%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
35
181
1949
21
63
115
1242
hydrocortisone aceponate
D07AC16 [21602135]
5.9e-01
1.4e+00
—
—
2.8e+00
1.7e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.76%
cases:15.44%
controls:4.83%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
35
181
1949
21
63
115
1242
hydrocortisone
D07AA02 [21602102]
5.9e-01
1.4e+00
—
—
2.8e+00
1.7e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.76%
cases:15.44%
controls:4.83%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
35
181
1949
21
63
115
1242
hydrocortisone buteprate
D07AB11 [21602115]
5.9e-01
1.4e+00
—
—
2.8e+00
1.7e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.76%
cases:15.44%
controls:4.83%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
35
181
1949
21
63
115
1242
hydrocortisone
C05AA01 [21601608]
5.9e-01
1.4e+00
—
—
2.8e+00
1.6e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.81%
cases:15.44%
controls:4.90%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
36
181
1948
21
64
115
1241
hydrocortisone
A07EA02 [21600654]
5.9e-01
1.4e+00
—
—
2.8e+00
1.6e+00
1.3e+00
cases:13.76%
controls:8.11%
cases:10.09%
controls:2.72%
—
—
—
—
cases:4.61%
controls:0.28%
cases:8.59%
controls:1.81%
cases:15.44%
controls:4.90%
30
176
188
1994
22
59
196
2111
—
—
10
6
207
2154
17
36
181
1948
21
64
115
1241
Dermatitis, unspecified
L30.9 [45572271]
1.7e-01
1.5e+00
—
—
2.8e+00
1.7e+00
9.5e-01
cases:5.05%
controls:4.29%
cases:5.50%
controls:1.34%
—
—
—
—
cases:3.69%
controls:0.23%
cases:7.58%
controls:1.46%
cases:8.82%
controls:3.60%
11
93
207
2077
12
29
206
2141
—
—
8
5
209
2155
15
29
183
1955
12
47
124
1258
Case Management Agency
251B00000X [38004193]
2.2e-02
3.3e-01
6.7e-01
4.7e+00
5.9e-01
3.4e-01
2.5e-01
cases:72.02%
controls:71.57%
cases:73.85%
controls:67.10%
cases:46.79%
controls:31.01%
cases:68.81%
controls:1.98%
cases:42.86%
controls:29.44%
cases:73.23%
controls:66.08%
cases:70.59%
controls:65.06%
157
1553
61
617
161
1456
57
714
102
673
116
1497
150
43
68
2127
93
636
124
1524
145
1311
53
673
96
849
40
456
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.9e-01
7.2e-01
—
—
3.1e+00
1.5e+00
9.6e-01
cases:9.17%
controls:7.70%
cases:5.96%
controls:3.00%
—
—
—
—
cases:5.99%
controls:0.28%
cases:12.63%
controls:3.02%
cases:15.44%
controls:6.51%
20
167
198
2003
13
65
205
2105
—
—
13
6
204
2154
25
60
173
1924
21
85
115
1220
Supplier / Service Provider
OMOP5117446 [33004]
-1.9e-01
-8.1e-01
-1.0e+50
—
—
2.7e+00
2.7e+00
cases:24.77%
controls:28.53%
cases:4.13%
controls:8.85%
cases:0.00%
controls:0.65%
—
—
—
—
cases:6.57%
controls:0.45%
cases:11.76%
controls:0.84%
54
619
164
1551
9
192
209
1978
0
14
218
2156
—
—
13
9
185
1975
16
11
120
1294
hydrocortisone
S02BA01 [21605166]
6.1e-01
1.4e+00
—
—
2.3e+00
1.1e+00
1.1e+00
cases:12.39%
controls:7.14%
cases:8.72%
controls:2.30%
—
—
—
—
cases:2.76%
controls:0.28%
cases:4.55%
controls:1.61%
cases:11.03%
controls:4.14%
27
155
191
2015
19
50
199
2120
—
—
6
6
211
2154
9
32
189
1952
15
54
121
1251
Pharmacy visit
OMOP4822462 [581458]
4.1e-02
2.8e-01
4.8e-01
3.5e+00
7.7e-01
3.6e-01
1.7e-01
cases:91.74%
controls:91.43%
cases:82.57%
controls:78.11%
cases:51.38%
controls:39.54%
cases:36.70%
controls:1.80%
cases:58.53%
controls:39.58%
cases:84.85%
controls:79.64%
cases:94.12%
controls:93.10%
200
1984
18
186
180
1695
38
475
112
858
106
1312
80
39
138
2131
127
855
90
1305
168
1580
30
404
128
1215
8
90
Outpatient Visit
OP [9202]
1.0e-01
2.2e-01
3.1e-01
3.7e+00
6.2e-01
4.1e-01
3.1e-01
cases:74.31%
controls:72.35%
cases:50.00%
controls:44.42%
cases:10.55%
controls:7.97%
cases:8.26%
controls:0.23%
cases:13.82%
controls:7.96%
cases:51.01%
controls:40.98%
cases:73.53%
controls:67.13%
162
1570
56
600
109
964
109
1206
23
173
195
1997
18
5
200
2165
30
172
187
1988
101
813
97
1171
100
876
36
429
Other specified counselling
Z71.8 [45581061]
3.9e-01
9.4e-01
—
—
2.3e+00
7.9e-01
7.4e-01
cases:12.39%
controls:8.76%
cases:9.63%
controls:4.01%
—
—
—
—
cases:2.76%
controls:0.28%
cases:7.58%
controls:3.58%
cases:14.71%
controls:7.59%
27
190
191
1980
21
87
197
2083
—
—
6
6
211
2154
15
71
183
1913
20
99
116
1206
combinations of corticosteroids
D07XB30 [21602188]
6.7e-01
1.3e+00
—
—
1.8e+00
7.6e-01
1.0e+00
cases:18.35%
controls:10.28%
cases:11.01%
controls:3.13%
—
—
—
—
cases:2.30%
controls:0.37%
cases:7.07%
controls:3.43%
cases:20.59%
controls:8.43%
40
223
178
1947
24
68
194
2102
—
—
5
8
212
2152
14
68
184
1916
28
110
108
1195
combinations of corticosteroids
D07AB30 [21602118]
6.7e-01
1.3e+00
—
—
1.8e+00
7.6e-01
1.0e+00
cases:18.35%
controls:10.28%
cases:11.01%
controls:3.13%
—
—
—
—
cases:2.30%
controls:0.37%
cases:7.07%
controls:3.43%
cases:20.59%
controls:8.43%
40
223
178
1947
24
68
194
2102
—
—
5
8
212
2152
14
68
184
1916
28
110
108
1195
Infectious Disease
44 [38004484]
1.1e+00
1.8e+00
—
—
—
1.9e+00
9.5e-01
cases:6.88%
controls:2.44%
cases:2.75%
controls:0.46%
—
—
—
—
—
—
cases:3.54%
controls:0.55%
cases:3.68%
controls:1.46%
15
53
203
2117
6
10
212
2160
—
—
—
7
11
191
1973
5
19
131
1286
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.0e+00
1.8e+00
—
—
—
5.9e-01
1.2e+00
cases:10.09%
controls:3.87%
cases:5.05%
controls:0.88%
—
—
—
—
—
—
cases:2.53%
controls:1.41%
cases:8.82%
controls:2.91%
22
84
196
2086
11
19
207
2151
—
—
—
5
28
193
1956
12
38
124
1267
miconazole
S02AA13 [21605159]
2.7e+00
—
—
—
—
—
—
cases:3.21%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
7
5
211
2165
—
—
—
—
—
—
ivermectin; oral
P02CF01 [21604957]
—
2.5e+00
—
1.0e+50
1.0e+50
—
—
—
—
cases:2.75%
controls:0.23%
—
—
cases:16.06%
controls:0.00%
cases:10.14%
controls:0.00%
—
—
—
—
—
6
5
212
2165
—
35
0
183
2170
22
0
195
2160
—
—
Telehealth
OMOP5556618 [722455]
2.9e-01
8.0e-01
9.3e-01
1.0e+50
1.6e+00
7.4e-01
3.3e-01
cases:31.65%
controls:25.81%
cases:12.39%
controls:5.99%
cases:2.75%
controls:1.11%
cases:2.29%
controls:0.00%
cases:4.15%
controls:0.83%
cases:11.11%
controls:5.65%
cases:19.85%
controls:15.17%
69
560
149
1610
27
130
191
2040
6
24
212
2146
5
0
213
2170
9
18
208
2142
22
112
176
1872
27
198
109
1107
Headache
R51.80 [2000503603]
9.7e-01
—
—
—
—
1.0e+00
1.5e+00
cases:7.34%
controls:2.90%
—
—
—
—
—
—
—
—
cases:2.53%
controls:0.91%
cases:10.29%
controls:2.61%
16
63
202
2107
—
—
—
—
5
18
193
1966
14
34
122
1271
Other specified anxiety disorders
F41.8 [45595908]
2.3e+00
—
—
—
—
—
-1.0e+50
cases:2.75%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
6
6
212
2164
—
—
—
—
—
0
10
136
1295
Emergency Room Visit
ER [9203]
4.9e-01
6.3e-01
1.3e+00
1.0e+50
1.6e+00
5.7e-01
6.3e-01
cases:37.16%
controls:26.59%
cases:14.68%
controls:8.39%
cases:2.75%
controls:0.74%
cases:14.22%
controls:0.00%
cases:3.69%
controls:0.74%
cases:14.14%
controls:8.52%
cases:37.50%
controls:24.14%
81
577
137
1593
32
182
186
1988
6
16
212
2154
31
0
187
2170
8
16
209
2144
28
169
170
1815
51
315
85
990
Other and unspecified abdominal pain
R10.4 [45568113]
1.0e+00
1.2e+00
—
—
—
8.1e-01
5.6e-01
cases:16.51%
controls:6.54%
cases:5.96%
controls:1.94%
—
—
—
—
—
—
cases:5.05%
controls:2.32%
cases:9.56%
controls:5.67%
36
142
182
2028
13
42
205
2128
—
—
—
10
46
188
1938
13
74
123
1231
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
1.8e+00
2.2e+00
—
—
—
—
1.6e+00
cases:2.75%
controls:0.46%
cases:3.21%
controls:0.37%
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.77%
6
10
212
2160
7
8
211
2162
—
—
—
—
5
10
131
1295
fexofenadine; oral
R06AX26 [21603525]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:0.54%
—
—
—
—
—
—
6
7
130
1298
ispaghula (psylla seeds); oral
A06AC01 [21600555]
9.0e-01
6.4e-01
—
—
—
9.0e-01
1.2e+00
cases:9.17%
controls:3.96%
cases:4.13%
controls:2.21%
—
—
—
—
—
—
cases:5.05%
controls:2.12%
cases:11.76%
controls:3.75%
20
86
198
2084
9
48
209
2122
—
—
—
10
42
188
1942
16
49
120
1256
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
1.0e+00
2.1e+00
—
—
—
1.7e+00
1.6e+00
cases:4.13%
controls:1.52%
cases:3.67%
controls:0.46%
—
—
—
—
—
—
cases:2.53%
controls:0.45%
cases:4.41%
controls:0.92%
9
33
209
2137
8
10
210
2160
—
—
—
5
9
193
1975
6
12
130
1293
Laboratory Visit
OMOP4822461 [32036]
2.7e-02
1.8e-01
3.9e-01
2.1e+00
3.8e-01
2.4e-01
1.3e-01
cases:61.01%
controls:60.37%
cases:55.05%
controls:50.60%
cases:20.18%
controls:14.56%
cases:5.96%
controls:0.78%
cases:18.89%
controls:13.70%
cases:55.05%
controls:49.04%
cases:59.56%
controls:56.40%
133
1310
85
860
120
1098
98
1072
44
316
174
1854
13
17
205
2153
41
296
176
1864
109
973
89
1011
81
736
55
569
betamethasone
A07EA04 [21600656]
5.4e-01
1.0e+00
—
—
—
1.1e+00
9.9e-01
cases:11.01%
controls:6.73%
cases:5.50%
controls:2.07%
—
—
—
—
—
—
cases:8.08%
controls:2.87%
cases:15.44%
controls:6.36%
24
146
194
2024
12
45
206
2125
—
—
—
16
57
182
1927
21
83
115
1222
betamethasone
C05AA05 [21601610]
5.4e-01
1.0e+00
—
—
—
1.1e+00
9.9e-01
cases:11.01%
controls:6.73%
cases:5.50%
controls:2.07%
—
—
—
—
—
—
cases:8.08%
controls:2.87%
cases:15.44%
controls:6.36%
24
146
194
2024
12
45
206
2125
—
—
—
16
57
182
1927
21
83
115
1222
betamethasone
D07AC01 [21602120]
5.4e-01
1.0e+00
—
—
—
1.1e+00
9.9e-01
cases:11.01%
controls:6.73%
cases:5.50%
controls:2.07%
—
—
—
—
—
—
cases:8.08%
controls:2.87%
cases:15.44%
controls:6.36%
24
146
194
2024
12
45
206
2125
—
—
—
16
57
182
1927
21
83
115
1222
betamethasone
S02BA07 [21605169]
5.4e-01
1.0e+00
—
—
—
1.1e+00
9.9e-01
cases:11.01%
controls:6.73%
cases:5.50%
controls:2.07%
—
—
—
—
—
—
cases:8.08%
controls:2.87%
cases:15.44%
controls:6.36%
24
146
194
2024
12
45
206
2125
—
—
—
16
57
182
1927
21
83
115
1222
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
8.6e-01
2.1e+00
—
—
—
1.4e+00
8.5e-01
cases:3.21%
controls:1.38%
cases:3.21%
controls:0.41%
—
—
—
—
—
—
cases:2.53%
controls:0.60%
cases:3.68%
controls:1.61%
7
30
211
2140
7
9
211
2161
—
—
—
5
12
193
1972
5
21
131
1284
fluoxetine; oral
N06AB03 [21604711]
1.4e+00
1.6e+00
—
—
—
2.0e+00
1.4e+00
cases:4.13%
controls:1.01%
cases:2.29%
controls:0.46%
—
—
—
—
—
—
cases:3.03%
controls:0.40%
cases:3.68%
controls:0.92%
9
22
209
2148
5
10
213
2160
—
—
—
6
8
192
1976
5
12
131
1293
Opiates [Presence] in Urine
3879-4 [3027008]
5.6e-01
1.9e+00
—
—
—
1.6e+00
9.0e-01
cases:4.13%
controls:2.40%
cases:3.67%
controls:0.55%
—
—
—
—
—
—
cases:2.53%
controls:0.50%
cases:3.68%
controls:1.53%
9
52
209
2118
8
12
210
2158
—
—
—
5
10
193
1974
5
20
131
1285
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
1.9e+00
—
—
—
—
—
-1.0e+50
cases:3.21%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
7
11
211
2159
—
—
—
—
—
0
9
136
1296
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
4.6e-01
1.3e+00
—
—
—
—
1.9e+00
cases:2.75%
controls:1.75%
cases:2.75%
controls:0.74%
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.84%
6
38
212
2132
6
16
212
2154
—
—
—
—
7
11
129
1294
FEV1
20150-9 [3024653]
4.6e-01
1.3e+00
—
—
—
—
1.9e+00
cases:2.75%
controls:1.75%
cases:2.75%
controls:0.74%
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.84%
6
38
212
2132
6
16
212
2154
—
—
—
—
7
11
129
1294
FEV1/FVC
19926-5 [3011505]
4.6e-01
1.3e+00
—
—
—
—
1.9e+00
cases:2.75%
controls:1.75%
cases:2.75%
controls:0.74%
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.84%
6
38
212
2132
6
16
212
2154
—
—
—
—
7
11
129
1294
chlorhexidine
D09AA12 [21602275]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
chlorhexidine, combinations
D08AC52 [21602208]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
chlorhexidine
S02AA09 [21605155]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
hydrocortisone
D07XA01 [21602180]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
Amphetamines [Presence] in Urine
3349-8 [3027944]
5.6e-01
1.8e+00
—
—
—
1.7e+00
—
cases:4.13%
controls:2.40%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
cases:2.53%
controls:0.45%
—
—
9
52
209
2118
8
13
210
2157
—
—
—
5
9
193
1975
—
chlorhexidine
S03AA04 [21605193]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
triamcinolone and antiseptics
D07BB03 [21602150]
9.5e-01
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.58%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
56
204
2114
8
13
210
2157
—
—
—
—
5
14
131
1291
hydrocortisone and antiseptics
D07BA04 [21602146]
1.0e+00
1.8e+00
—
—
—
—
1.3e+00
cases:6.42%
controls:2.44%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
53
204
2117
8
13
210
2157
—
—
—
—
5
14
131
1291
Cannabinoids [Presence] in Urine
3427-2 [3028300]
5.6e-01
1.8e+00
—
—
—
1.6e+00
9.0e-01
cases:4.13%
controls:2.40%
cases:3.67%
controls:0.60%
—
—
—
—
—
—
cases:2.53%
controls:0.50%
cases:3.68%
controls:1.53%
9
52
209
2118
8
13
210
2157
—
—
—
5
10
193
1974
5
20
131
1285
Cocaine [Presence] in Urine
3397-7 [3016879]
7.3e-01
1.8e+00
—
—
—
1.7e+00
1.0e+00
cases:4.13%
controls:2.03%
cases:3.21%
controls:0.55%
—
—
—
—
—
—
cases:2.53%
controls:0.45%
cases:3.68%
controls:1.38%
9
44
209
2126
7
12
211
2158
—
—
—
5
9
193
1975
5
18
131
1287
clonazepam; oral, parenteral
N03AE01 [21604415]
1.8e+00
—
—
—
—
-1.0e+50
—
cases:3.67%
controls:0.65%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
8
14
210
2156
—
—
—
—
0
6
198
1978
—
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
1.7e+00
—
—
—
—
—
-1.0e+50
cases:4.59%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
10
18
208
2152
—
—
—
—
—
0
12
136
1293
Skin texture symptom/complaint
S21 [2002000986]
—
8.8e-01
—
—
—
1.7e+00
1.1e+00
—
—
cases:2.29%
controls:0.97%
—
—
—
—
—
—
cases:4.04%
controls:0.76%
cases:5.15%
controls:1.84%
—
5
21
213
2149
—
—
—
8
15
190
1969
7
24
129
1281
tiotropium bromide; inhalant
R03BB04 [21603296]
1.0e+00
1.6e+00
—
—
—
1.2e+00
1.0e+00
cases:3.21%
controls:1.20%
cases:3.67%
controls:0.74%
—
—
—
—
—
—
cases:3.03%
controls:0.91%
cases:3.68%
controls:1.38%
7
26
211
2144
8
16
210
2154
—
—
—
6
18
192
1966
5
18
131
1287
No disease
A97 [2002000230]
-7.1e-02
6.8e-01
—
—
—
1.6e+00
9.4e-01
cases:2.75%
controls:2.95%
cases:3.21%
controls:1.66%
—
—
—
—
—
—
cases:4.55%
controls:0.96%
cases:6.62%
controls:2.68%
6
64
212
2106
7
36
211
2134
—
—
—
9
19
189
1965
9
35
127
1270
sodium fluoride; oral
A01AA01 [21600005]
1.6e+00
—
—
—
—
—
1.3e+00
cases:6.42%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.07%
14
30
204
2140
—
—
—
—
—
5
14
131
1291
cefalexin; oral
J01DB01 [21602870]
2.8e-01
5.2e-01
—
—
1.6e+00
-2.1e-02
1.9e-01
cases:33.94%
controls:27.97%
cases:12.84%
controls:8.06%
—
—
—
—
cases:4.15%
controls:0.88%
cases:7.07%
controls:7.21%
cases:27.94%
controls:24.21%
74
607
144
1563
28
175
190
1995
—
—
9
19
208
2141
14
143
184
1841
38
316
98
989
ferrous glycine sulfate; oral
B03AA01 [21601080]
1.6e+00
—
—
—
—
—
—
cases:4.13%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
9
19
209
2151
—
—
—
—
—
—
betamethasone
S03BA03 [21605203]
1.2e-01
1.4e+00
—
—
—
1.3e+00
1.5e+00
cases:2.75%
controls:2.44%
cases:2.29%
controls:0.55%
—
—
—
—
—
—
cases:3.03%
controls:0.81%
cases:8.09%
controls:1.84%
6
53
212
2117
5
12
213
2158
—
—
—
6
16
192
1968
11
24
125
1281
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
4.7e-01
6.6e-01
—
—
—
9.8e-01
1.5e+00
cases:5.96%
controls:3.82%
cases:2.29%
controls:1.20%
—
—
—
—
—
—
cases:3.54%
controls:1.36%
cases:9.56%
controls:2.22%
13
83
205
2087
5
26
213
2144
—
—
—
7
27
191
1957
13
29
123
1276
salbutamol; inhalant
R03AC02 [21603256]
3.6e-01
3.0e-01
1.5e+00
—
—
2.5e-01
5.1e-01
cases:22.48%
controls:16.77%
cases:10.09%
controls:7.70%
cases:4.59%
controls:1.06%
—
—
—
—
cases:10.10%
controls:8.06%
cases:21.32%
controls:13.95%
49
364
169
1806
22
167
196
2003
10
23
208
2147
—
—
20
160
178
1824
29
182
107
1123
Fungus identified in Specimen by Culture
580-1 [3000494]
2.9e-01
—
—
—
—
1.7e+00
1.5e+00
cases:4.13%
controls:3.13%
—
—
—
—
—
—
—
—
cases:2.53%
controls:0.45%
cases:7.35%
controls:1.76%
9
68
209
2102
—
—
—
—
5
9
193
1975
10
23
126
1282
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
8.0e-02
1.0e+00
—
—
—
1.3e+00
1.5e+00
cases:5.96%
controls:5.53%
cases:3.21%
controls:1.20%
—
—
—
—
—
—
cases:3.03%
controls:0.81%
cases:9.56%
controls:2.38%
13
120
205
2050
7
26
211
2144
—
—
—
6
16
192
1968
13
31
123
1274
nortriptyline; oral, parenteral
N06AA10 [21604697]
1.5e+00
—
—
—
—
—
—
cases:4.59%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
—
—
10
24
208
2146
—
—
—
—
—
—
diclofenac
D11AX18 [21602355]
5.8e-01
5.5e-01
—
—
—
—
1.4e+00
cases:5.05%
controls:2.90%
cases:2.29%
controls:1.34%
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.22%
11
63
207
2107
5
29
213
2141
—
—
—
—
12
29
124
1276
diclofenac; ointment
M02AA15 [21604051]
5.8e-01
5.5e-01
—
—
—
—
1.4e+00
cases:5.05%
controls:2.90%
cases:2.29%
controls:1.34%
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.22%
11
63
207
2107
5
29
213
2141
—
—
—
—
12
29
124
1276
Pulpitis
K04.0 [45591570]
1.4e+00
—
—
—
—
—
—
cases:5.05%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
—
—
11
28
207
2142
—
—
—
—
—
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
2.6e-01
—
—
—
—
1.5e+00
1.4e+00
cases:3.21%
controls:2.49%
—
—
—
—
—
—
—
—
cases:2.53%
controls:0.55%
cases:7.35%
controls:1.92%
7
54
211
2116
—
—
—
—
5
11
193
1973
10
25
126
1280
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
3.2e-01
7.4e-01
—
—
—
8.7e-01
1.4e+00
cases:6.42%
controls:4.75%
cases:2.75%
controls:1.34%
—
—
—
—
—
—
cases:3.54%
controls:1.51%
cases:9.56%
controls:2.61%
14
103
204
2067
6
29
212
2141
—
—
—
7
30
191
1954
13
34
123
1271
saccharomyces boulardii; oral
A07FA02 [21600670]
1.4e+00
—
—
—
—
—
—
cases:5.50%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
12
32
206
2138
—
—
—
—
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.4e-01
6.0e-01
9.5e-01
—
8.0e-01
7.5e-01
3.3e-01
cases:46.79%
controls:36.13%
cases:25.69%
controls:15.99%
cases:5.50%
controls:2.21%
—
—
cases:4.61%
controls:2.13%
cases:26.77%
controls:14.72%
cases:40.44%
controls:32.80%
102
784
116
1386
56
347
162
1823
12
48
206
2122
—
10
46
207
2114
53
292
145
1692
55
428
81
877
ibuprofen
R02AX02 [1588667]
4.4e-01
6.0e-01
9.5e-01
—
8.0e-01
7.5e-01
3.3e-01
cases:46.79%
controls:36.13%
cases:25.69%
controls:15.99%
cases:5.50%
controls:2.21%
—
—
cases:4.61%
controls:2.13%
cases:26.77%
controls:14.72%
cases:40.44%
controls:32.80%
102
784
116
1386
56
347
162
1823
12
48
206
2122
—
10
46
207
2114
53
292
145
1692
55
428
81
877
COVID-19, virus not identified
U07.2 [45756094]
1.2e-01
7.3e-01
—
—
-1.0e+50
1.3e+00
3.0e-01
cases:8.26%
controls:7.42%
cases:4.13%
controls:2.03%
—
—
—
—
cases:0.00%
controls:0.28%
cases:5.56%
controls:1.56%
cases:6.62%
controls:4.98%
18
161
200
2009
9
44
209
2126
—
—
0
6
217
2154
11
31
187
1953
9
65
127
1240
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
1.3e+00
—
—
—
—
—
—
cases:5.05%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
—
—
11
31
207
2139
—
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
5.9e-01
5.8e-01
—
—
—
—
1.3e+00
cases:5.05%
controls:2.86%
cases:2.75%
controls:1.57%
—
—
—
—
—
—
—
—
cases:8.82%
controls:2.68%
11
62
207
2108
6
34
212
2136
—
—
—
—
12
35
124
1270
Ankle symptom/complaint
L16 [2002000640]
1.2e+00
1.5e+00
—
—
—
—
—
cases:5.50%
controls:1.66%
cases:2.29%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
12
36
206
2134
5
11
213
2159
—
—
—
—
—
Throat symptom/complaint
R21 [2002000891]
7.9e-01
5.8e-01
—
—
—
9.1e-01
1.2e+00
cases:10.55%
controls:5.07%
cases:2.75%
controls:1.57%
—
—
—
—
—
—
cases:4.04%
controls:1.66%
cases:11.03%
controls:3.52%
23
110
195
2060
6
34
212
2136
—
—
—
8
33
190
1951
15
46
121
1259
Chronic apical periodontitis
K04.5 [45586691]
8.7e-01
8.8e-01
—
—
—
8.9e-01
1.2e+00
cases:8.26%
controls:3.64%
cases:4.13%
controls:1.75%
—
—
—
—
—
—
cases:3.03%
controls:1.26%
cases:10.29%
controls:3.30%
18
79
200
2091
9
38
209
2132
—
—
—
6
25
192
1959
14
43
122
1262
Counselling related to known health issue
SPAT1310 [2001700411]
5.3e-01
1.1e+00
—
—
—
5.2e-01
1.2e+00
cases:10.55%
controls:6.50%
cases:5.05%
controls:1.80%
—
—
—
—
—
—
cases:2.53%
controls:1.51%
cases:11.76%
controls:3.91%
23
141
195
2029
11
39
207
2131
—
—
—
5
30
193
1954
16
51
120
1254
propranolol; oral, parenteral
C07AA05 [21601670]
2.9e-01
5.4e-01
—
—
-1.0e+50
7.4e-01
1.2e+00
cases:7.34%
controls:5.58%
cases:4.13%
controls:2.44%
—
—
—
—
cases:0.00%
controls:0.28%
cases:6.06%
controls:2.97%
cases:13.24%
controls:4.52%
16
121
202
2049
9
53
209
2117
—
—
0
6
217
2154
12
59
186
1925
18
59
118
1246
chloramphenicol
S03AA08 [21605197]
4.2e-01
1.1e+00
1.6e+00
—
—
4.0e-01
6.8e-01
cases:16.97%
controls:11.80%
cases:11.93%
controls:4.29%
cases:2.29%
controls:0.46%
—
—
—
—
cases:5.05%
controls:3.43%
cases:17.65%
controls:9.81%
37
256
181
1914
26
93
192
2077
5
10
213
2160
—
—
10
68
188
1916
24
128
112
1177
chloramphenicol
S01AA01 [21603554]
4.2e-01
1.1e+00
1.6e+00
—
—
4.0e-01
6.8e-01
cases:16.97%
controls:11.80%
cases:11.93%
controls:4.29%
cases:2.29%
controls:0.46%
—
—
—
—
cases:5.05%
controls:3.43%
cases:17.65%
controls:9.81%
37
256
181
1914
26
93
192
2077
5
10
213
2160
—
—
10
68
188
1916
24
128
112
1177
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
1.1e+00
-1.0e+50
—
—
-1.0e+50
1.4e+00
6.7e-01
cases:10.55%
controls:3.78%
cases:0.00%
controls:1.38%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.03%
controls:0.76%
cases:7.35%
controls:3.91%
23
82
195
2088
0
30
218
2140
—
—
0
5
217
2155
6
15
192
1969
10
51
126
1254
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.0e-01
3.7e-01
4.3e-01
—
1.0e+00
4.6e-01
4.2e-01
cases:47.25%
controls:42.26%
cases:30.28%
controls:23.13%
cases:5.96%
controls:3.96%
—
—
cases:8.76%
controls:3.33%
cases:30.81%
controls:21.93%
cases:45.59%
controls:35.56%
103
917
115
1253
66
502
152
1668
13
86
205
2084
—
19
72
198
2088
61
435
137
1549
62
464
74
841
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
5.7e-01
8.5e-01
—
—
—
7.7e-01
1.0e+00
cases:11.47%
controls:6.82%
cases:5.05%
controls:2.21%
—
—
—
—
—
—
cases:3.54%
controls:1.66%
cases:11.76%
controls:4.60%
25
148
193
2022
11
48
207
2122
—
—
—
7
33
191
1951
16
60
120
1245
Intraoral radiographic dental examination
EB1AA [2001301903]
4.5e-01
4.9e-01
—
—
—
1.0e+00
6.1e-01
cases:21.10%
controls:14.61%
cases:7.34%
controls:4.61%
—
—
—
—
—
—
cases:9.60%
controls:3.73%
cases:19.12%
controls:11.34%
46
317
172
1853
16
100
202
2070
—
—
—
19
74
179
1910
26
148
110
1157
Pain localized to upper abdomen
R10.1 [45568111]
1.0e+00
9.3e-01
—
—
—
—
3.9e-01
cases:6.88%
controls:2.63%
cases:3.21%
controls:1.29%
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.53%
15
57
203
2113
7
28
211
2142
—
—
—
—
5
33
131
1272
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
6.1e-02
-4.5e-02
—
—
—
—
9.8e-01
cases:7.80%
controls:7.37%
cases:2.29%
controls:2.40%
—
—
—
—
—
—
—
—
cases:13.24%
controls:5.44%
17
160
201
2010
5
52
213
2118
—
—
—
—
18
71
118
1234
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
5.4e-01
5.9e-01
—
—
—
3.2e-01
9.3e-01
cases:13.76%
controls:8.53%
cases:5.50%
controls:3.13%
—
—
—
—
—
—
cases:4.55%
controls:3.33%
cases:16.91%
controls:7.43%
30
185
188
1985
12
68
206
2102
—
—
—
9
66
189
1918
23
97
113
1208
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
3.6e-01
8.9e-01
—
—
—
7.6e-01
9.1e-01
cases:16.97%
controls:12.49%
cases:8.26%
controls:3.55%
—
—
—
—
—
—
cases:6.06%
controls:2.92%
cases:16.18%
controls:7.20%
37
271
181
1899
18
77
200
2093
—
—
—
12
58
186
1926
22
94
114
1211
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-1.1e-01
1.7e-01
—
—
—
-2.4e-02
8.8e-01
cases:9.63%
controls:10.60%
cases:5.05%
controls:4.29%
—
—
—
—
—
—
cases:4.04%
controls:4.13%
cases:18.38%
controls:8.58%
21
230
197
1940
11
93
207
2077
—
—
—
8
82
190
1902
25
112
111
1193
codeine and paracetamol
N02AJ06 [1123647]
5.3e-01
8.6e-01
—
—
—
7.1e-01
1.9e-01
cases:22.48%
controls:14.52%
cases:9.63%
controls:4.33%
—
—
—
—
—
—
cases:7.58%
controls:3.88%
cases:11.03%
controls:9.27%
49
315
169
1855
21
94
197
2076
—
—
—
15
77
183
1907
15
121
121
1184
Acute upper respiratory infection, unspecified
J06.9 [45562437]
3.0e-01
4.4e-01
8.5e-01
—
—
8.4e-01
6.2e-01
cases:22.02%
controls:17.28%
cases:13.30%
controls:8.99%
cases:2.75%
controls:1.20%
—
—
—
—
cases:17.17%
controls:8.22%
cases:25.00%
controls:15.17%
48
375
170
1795
29
195
189
1975
6
26
212
2144
—
—
34
163
164
1821
34
198
102
1107
metronidazole; oral, rectal
P01AB01 [21604857]
8.3e-01
7.6e-01
—
—
—
—
-2.8e-02
cases:16.06%
controls:7.70%
cases:3.21%
controls:1.52%
—
—
—
—
—
—
—
—
cases:5.15%
controls:5.29%
35
167
183
2003
7
33
211
2137
—
—
—
—
7
69
129
1236
Low back pain
M54.5 [45553207]
8.2e-01
6.5e-01
—
—
-1.0e+50
—
7.0e-02
cases:14.22%
controls:6.77%
cases:5.50%
controls:2.95%
—
—
—
—
cases:0.00%
controls:0.23%
—
—
cases:8.09%
controls:7.59%
31
147
187
2023
12
64
206
2106
—
—
0
5
217
2155
—
11
99
125
1206
Psychiatry
26 [38004469]
7.3e-01
7.7e-01
8.1e-01
—
6.2e-01
5.8e-01
4.5e-01
cases:13.76%
controls:7.14%
cases:7.80%
controls:3.78%
cases:3.67%
controls:1.66%
—
—
cases:2.30%
controls:1.25%
cases:6.06%
controls:3.48%
cases:11.03%
controls:7.36%
30
155
188
2015
17
82
201
2088
8
36
210
2134
—
5
27
212
2133
12
69
186
1915
15
96
121
1209
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.4e-01
2.6e-01
—
—
7.8e-01
6.5e-02
7.2e-01
cases:29.82%
controls:23.27%
cases:10.09%
controls:7.97%
—
—
—
—
cases:2.30%
controls:1.06%
cases:7.07%
controls:6.65%
cases:27.94%
controls:15.86%
65
505
153
1665
22
173
196
1997
—
—
5
23
212
2137
14
132
184
1852
38
207
98
1098
Other blockage of nerve
WX290 [2001310792]
6.8e-01
6.1e-01
-1.0e+50
—
-1.0e+50
8.1e-01
7.2e-01
cases:23.85%
controls:13.73%
cases:7.80%
controls:4.38%
cases:0.00%
controls:0.69%
—
—
cases:0.00%
controls:0.56%
cases:8.08%
controls:3.78%
cases:19.85%
controls:10.80%
52
298
166
1872
17
95
201
2075
0
15
218
2155
—
0
12
217
2148
16
75
182
1909
27
141
109
1164
Simple examination of mouth
SAA01 [2001310274]
6.7e-01
5.4e-01
—
—
3.9e-01
5.3e-01
5.5e-01
cases:41.74%
controls:26.87%
cases:18.35%
controls:11.57%
—
—
—
—
cases:2.30%
controls:1.57%
cases:18.18%
controls:11.59%
cases:36.03%
controls:24.44%
91
583
127
1587
40
251
178
1919
—
—
5
34
212
2126
36
230
162
1754
49
319
87
986
Outpatient Hospital
22 [8756]
6.1e-01
-4.3e-02
—
—
1.4e+00
6.3e-01
1.4e-01
cases:24.77%
controls:15.21%
cases:3.67%
controls:3.82%
—
—
—
—
cases:2.30%
controls:0.60%
cases:7.07%
controls:3.88%
cases:14.71%
controls:13.03%
54
330
164
1840
8
83
210
2087
—
—
5
13
212
2147
14
77
184
1907
20
170
116
1135
Infiltration anesthesia
WX110 [2001310767]
5.9e-01
2.4e-01
—
—
-1.0e+50
4.8e-01
5.9e-01
cases:35.32%
controls:23.32%
cases:11.01%
controls:8.85%
—
—
—
—
cases:0.00%
controls:1.25%
cases:13.64%
controls:8.87%
cases:29.41%
controls:18.70%
77
506
141
1664
24
192
194
1978
—
—
0
27
217
2133
27
176
171
1808
40
244
96
1061
amoxicillin; oral, parenteral
J01CA04 [21602823]
5.3e-01
3.5e-01
—
—
—
6.6e-01
4.1e-01
cases:31.65%
controls:21.34%
cases:8.72%
controls:6.31%
—
—
—
—
—
—
cases:11.11%
controls:6.05%
cases:26.47%
controls:19.23%
69
463
149
1707
19
137
199
2033
—
—
—
22
120
176
1864
36
251
100
1054
Caries of dentine
K02.1 [45548134]
5.3e-01
1.7e-01
—
—
-1.0e+50
4.0e-01
6.3e-01
cases:31.19%
controls:21.11%
cases:10.09%
controls:8.62%
—
—
—
—
cases:0.00%
controls:1.30%
cases:11.62%
controls:8.06%
cases:27.21%
controls:16.55%
68
458
150
1712
22
187
196
1983
—
—
0
28
217
2132
23
160
175
1824
37
216
99
1089
Uncompl labour/delivery livebirth
W90 [2002001277]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
198
1979
—
methotrexate; oral, parenteral
L04AX03 [21603929]
—
5.5e-01
—
—
—
—
—
—
—
cases:2.29%
controls:1.34%
—
—
—
—
—
—
—
—
—
—
—
5
29
213
2141
—
—
—
—
—
formoterol; inhalant
R03AC13 [21603267]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.77%
0
13
218
2157
0
10
218
2160
—
—
—
0
9
198
1975
0
10
136
1295
Migraine without aura [common migraine]
G43.0 [45600784]
8.7e-01
7.4e-01
-1.0e+50
—
-1.0e+50
—
1.1e+00
cases:3.67%
controls:1.57%
cases:2.29%
controls:1.11%
cases:0.00%
controls:0.28%
—
—
cases:0.00%
controls:0.23%
—
—
cases:3.68%
controls:1.23%
8
34
210
2136
5
24
213
2146
0
6
218
2164
—
0
5
217
2155
—
5
16
131
1289
Chronic mucoid otitis media
H65.3 [45567124]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Bursitis/tendinitis/synovitis NOS
L87 [2002000706]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
chloramphenicol
S02AA01 [21605147]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.15%
—
—
—
—
—
—
5
15
131
1290
Guidance for breast-feeding and breast care
SPAT1200 [2001700301]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
0
6
198
1978
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
6.7e-01
—
—
—
—
—
5.2e-01
cases:2.75%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.22%
6
31
212
2139
—
—
—
—
—
5
29
131
1276
Contusion of lower back and pelvis
S30.0 [45549279]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
10
136
1295
Public health laboratory ask at order entry panel
81959-9 [21494755]
8.3e-03
—
—
—
-1.0e+50
—
—
cases:3.67%
controls:3.64%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
8
79
210
2091
—
—
—
0
5
217
2155
—
—
Hearing loss, unspecified
H91.9 [45547996]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
218
2165
0
5
218
2165
—
—
—
—
0
6
136
1299
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Immunohistochemistry procedure
117617002 [4035726]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
12
218
2158
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
4.3e-01
-1.5e-01
—
—
—
8.2e-01
6.3e-01
cases:18.35%
controls:12.72%
cases:2.75%
controls:3.18%
—
—
—
—
—
—
cases:7.58%
controls:3.48%
cases:19.85%
controls:11.65%
40
276
178
1894
6
69
212
2101
—
—
—
15
69
183
1915
27
152
109
1153
General counselling and advice on procreation
Z31.6 [45605118]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Psychological disorders other
P99 [2002000880]
2.1e+00
—
—
—
—
—
—
cases:2.29%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
5
6
213
2164
—
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
1.7e-01
—
—
—
—
—
—
cases:3.21%
controls:2.72%
—
—
—
—
—
—
—
—
—
—
—
—
7
59
211
2111
—
—
—
—
—
—
Bordetella pertussis Ab [Titer] in Serum
22116-8 [3025018]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
218
2160
—
—
—
—
—
—
Alveolitis of jaws
K10.3 [45591576]
1.6e+00
—
—
—
—
—
—
cases:2.29%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
5
10
213
2160
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
-2.9e-01
—
—
—
—
—
—
cases:2.29%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
66
213
2104
—
—
—
—
—
—
liraglutide; parenteral
A10BJ02 [1123630]
—
2.3e+00
—
—
—
—
—
—
—
cases:2.29%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
5
5
213
2165
—
—
—
—
—
Conisation of cervix uteri using diathermy or laser
LDC03 [2001306664]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
9
218
2161
—
—
—
—
—
0
6
136
1299
Chronic anal fissure
K60.1 [45557665]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
colestyramine; oral
C10AC01 [21601876]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
0
13
218
2157
—
—
—
0
6
198
1978
—
Fracture of other toe
S92.5 [45565210]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
10
218
2160
—
—
—
—
0
5
198
1979
—
Adverse effects in the therapeutic use of other and unspecified vaccines and biological substances
Y59 [45756621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
tocilizumab; parenteral
L04AC07 [21603921]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.00%
—
—
—
—
—
—
5
13
131
1292
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
1.5e-01
—
—
—
—
—
8.5e-01
cases:2.29%
controls:1.98%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.61%
5
43
213
2127
—
—
—
—
—
5
21
131
1284
Stomach Pathology biopsy report
66114-0 [40768797]
-7.6e-02
—
—
—
—
—
9.9e-01
cases:3.21%
controls:3.46%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:1.69%
7
75
211
2095
—
—
—
—
—
6
22
130
1283
Abdominal ultrasound examination
JN3AE [2001305555]
5.7e-01
—
—
—
—
—
—
cases:3.21%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
—
—
7
40
211
2130
—
—
—
—
—
—
Child behaviour symptom/complaint
P22 [2002000817]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
In vitrofertilization
Z31.2 [45581020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
rofecoxib; oral
M01AH02 [21603993]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Immunoglobulin typing, IgG
1712009 [4062490]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Fall on same level involving ice and snow
W00 [45756242]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
12
218
2158
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
2.2e-01
—
—
—
—
—
—
cases:2.75%
controls:2.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
48
212
2122
—
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
8.3e-01
—
—
—
—
—
—
cases:2.29%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
5
22
213
2148
—
—
—
—
—
—
Other extensive ultrasound examination of artery
PG1DE [2001309713]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
-4.2e-01
—
—
—
—
—
8.6e-01
cases:2.75%
controls:4.15%
—
—
—
—
—
—
—
—
—
—
cases:9.56%
controls:4.29%
6
90
212
2080
—
—
—
—
—
13
56
123
1249
Axillary plexus blockaced
WX204 [2001310780]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
buspirone; oral
N05BE01 [21604601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Joint symptom/complaint NOS
L20 [2002000644]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
11
218
2159
—
—
—
—
0
6
198
1978
—
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
7.8e-01
—
—
—
—
—
—
cases:2.29%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
213
2147
—
—
—
—
—
—
Hypothyroidism caused by autoimmune thyroiditis
E03.80 [2000501406]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.61%
0
7
218
2163
0
8
218
2162
—
—
—
0
6
198
1978
0
8
136
1297
Ultrasound examination of uterus and uterine appendages
SPAT1181 [2001700282]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
—
Spontaneous abortion, Complete or unspecified, without complication
O03.9 [45563040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
rabeprazole; oral
A02BC04 [21600099]
1.0e+00
—
—
—
—
-1.0e+50
—
cases:3.21%
controls:1.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
7
26
211
2144
—
—
—
—
0
9
198
1975
—
Phthiriasis
B85.3 [45590867]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:21.10%
controls:0.00%
cases:2.30%
controls:0.00%
—
—
—
—
—
—
—
46
0
172
2170
5
0
212
2160
—
—
Ear pain/earache
H01 [2002000475]
-2.5e-02
1.0e+00
—
—
—
—
1.4e+00
cases:2.29%
controls:2.35%
cases:2.29%
controls:0.83%
—
—
—
—
—
—
—
—
cases:5.88%
controls:1.46%
5
51
213
2119
5
18
213
2152
—
—
—
—
8
19
128
1286
Pityriasis versicolor
B36.0 [45537761]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
cefuroxime; oral, parenteral
J01DC02 [21602884]
9.3e-01
—
—
—
—
—
-1.0e+50
cases:2.29%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
5
20
213
2150
—
—
—
—
—
0
8
136
1297
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
LC2DE [2001306545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
frovatriptan; oral
N02CC07 [21604382]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
0
7
218
2163
—
—
—
0
6
198
1978
—
Split tooth for reasons other than trauma
K03.82 [2000502700]
3.6e-01
—
—
—
-1.0e+50
3.9e-01
1.8e-01
cases:3.21%
controls:2.26%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:3.54%
controls:2.42%
cases:7.35%
controls:6.21%
7
49
211
2121
—
—
—
0
8
217
2152
7
48
191
1936
10
81
126
1224
Adenotomy
EMB30 [2001302268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
218
2158
—
—
—
—
—
—
Norclozapine [Moles/volume] in Serum or Plasma
14851-0 [3008832]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
0
7
218
2163
—
—
—
—
—
Inpatient Hospital
21 [8717]
3.3e-01
1.2e-01
—
—
9.7e-01
1.8e-01
1.5e-01
cases:31.65%
controls:24.93%
cases:8.26%
controls:7.42%
—
—
—
—
cases:2.76%
controls:1.06%
cases:8.59%
controls:7.26%
cases:22.79%
controls:20.31%
69
541
149
1629
18
161
200
2009
—
—
6
23
211
2137
17
144
181
1840
31
265
105
1040
Hypothyroidism/myxoedema
T86 [2002001128]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
0
5
218
2165
—
—
—
—
0
13
136
1292
False labour
O47 [45606634]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
3.7e-01
1.2e-01
—
—
—
—
-5.9e-02
cases:9.17%
controls:6.50%
cases:2.75%
controls:2.44%
—
—
—
—
—
—
—
—
cases:5.15%
controls:5.44%
20
141
198
2029
6
53
212
2117
—
—
—
—
7
71
129
1234
Single live birth
Z37.0 [45571346]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
0
16
198
1968
—
Curettage of cervix uteri
LDA10 [2001306655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
9.0e-01
1.2e+00
—
—
—
—
—
cases:3.21%
controls:1.34%
cases:2.29%
controls:0.69%
—
—
—
—
—
—
—
—
—
—
7
29
211
2141
5
15
213
2155
—
—
—
—
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
4.7e-01
5.4e-01
—
—
—
-1.9e-01
3.2e-01
cases:10.09%
controls:6.54%
cases:5.05%
controls:3.00%
—
—
—
—
—
—
cases:2.53%
controls:3.02%
cases:8.82%
controls:6.59%
22
142
196
2028
11
65
207
2105
—
—
—
5
60
193
1924
12
86
124
1219
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
1.2e-01
—
—
—
—
—
1.4e+00
cases:2.75%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:1.15%
6
53
212
2117
—
—
—
—
—
6
15
130
1290
Prepatellar bursitis
M70.4 [45567632]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Revision of wound of skin of lower limb
QDB05 [2001309969]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Breast sympt/compl female other
X21 [2002001306]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
0
5
217
2155
0
10
198
1974
—
Change in faeces/bowel movements
D18 [2002000317]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
loperamide; oral
A07DA03 [21600646]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
0
17
218
2153
—
—
—
0
10
198
1974
—
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 [3027545]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
Breast lump/mass female
X19 [2002001304]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
218
2165
—
—
—
—
—
0
6
136
1299
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
loperamide oxide; oral
A07DA05 [21600648]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
0
17
218
2153
—
—
—
0
10
198
1974
—
hydrocortisone and antiinfectives
S02CA03 [21605175]
6.0e-01
1.5e+00
—
—
—
—
—
cases:4.59%
controls:2.58%
cases:2.75%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
10
56
208
2114
6
14
212
2156
—
—
—
—
—
Lump/swelling localized
S04 [2002000969]
-1.0e+50
-1.0e+50
—
—
—
1.2e+00
—
cases:0.00%
controls:1.84%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:2.53%
controls:0.76%
—
—
0
40
218
2130
0
18
218
2152
—
—
—
5
15
193
1969
—
Allergic urticaria
L50.0 [45581945]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Insertion of frozen embryo
TLW12 [2001306784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
scopolamine
A04AD01 [21600499]
—
—
-1.0e+50
—
—
—
8.7e-01
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:5.15%
controls:2.22%
—
—
0
5
218
2165
—
—
—
7
29
129
1276
Alzheimer disease with late onset
G30.1 [45552521]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
0
7
218
2163
—
—
—
—
—
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
9.7e-01
—
—
—
—
—
—
cases:5.50%
controls:2.17%
—
—
—
—
—
—
—
—
—
—
—
—
12
47
206
2123
—
—
—
—
—
—
Other Crohn disease
K50.8 [45533599]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
8
218
2162
—
—
—
0
9
198
1975
—
Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay
89640-7 [1175715]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Multiple inhalant allergen IgE Ab [Units/volume] in Serum
7492-2 [3002670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
ibandronic acid; oral, parenteral
M05BA06 [21604154]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Examination and observation for other specified reasons
Z04.8 [45552063]
2.2e-01
—
—
—
—
—
—
cases:2.29%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
—
—
5
40
213
2130
—
—
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
-1.1e-01
—
—
—
—
—
6.6e-02
cases:5.05%
controls:5.62%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:3.45%
11
122
207
2048
—
—
—
—
—
5
45
131
1260
Memory disturbance
P20 [2002000816]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
9
198
1975
—
Schizoaffective disorder, unspecified
F25.9 [45605490]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
mometasone
D07AC13 [21602132]
4.1e-01
1.0e+00
—
—
—
1.1e+00
1.0e+00
cases:5.50%
controls:3.73%
cases:3.21%
controls:1.20%
—
—
—
—
—
—
cases:4.04%
controls:1.41%
cases:8.09%
controls:2.99%
12
81
206
2089
7
26
211
2144
—
—
—
8
28
190
1956
11
39
125
1266
Eye, Other diagnostic procedure
F43 [2002000426]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Other local analgesia
WX199 [2001310775]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Pauciarticular juvenile arthritis
M08.4 [45582020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
Gastroenterology
10 [38004455]
-1.4e-02
5.6e-02
—
—
—
7.8e-01
-7.8e-02
cases:5.50%
controls:5.58%
cases:3.21%
controls:3.04%
—
—
—
—
—
—
cases:5.05%
controls:2.37%
cases:4.41%
controls:4.75%
12
121
206
2049
7
66
211
2104
—
—
—
10
47
188
1937
6
62
130
1243
Compl labour/ delivery livebirth
W92 [2002001279]
1.3e+00
-1.0e+50
—
—
—
—
-1.0e+50
cases:2.29%
controls:0.65%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
5
14
213
2156
0
6
218
2164
—
—
—
—
0
6
136
1299
Stomatognathic treatment, simple
SHA01 [2001310405]
6.2e-01
1.4e+00
—
—
—
—
1.4e+00
cases:3.21%
controls:1.75%
cases:2.29%
controls:0.55%
—
—
—
—
—
—
—
—
cases:6.62%
controls:1.69%
7
38
211
2132
5
12
213
2158
—
—
—
—
9
22
127
1283
amphotericin B; oral
A07AA07 [21600609]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Dedicated profession-specific psychiatric intervention, individual
IEY05 [2001304224]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
0
14
198
1970
—
Bicipital tendinitis
M75.2 [45557984]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Open wound of other parts of wrist and hand
S61.8 [45588506]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
—
Other hypothyroidism
E03 [45581337]
7.8e-01
—
—
—
—
—
—
cases:2.29%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
213
2147
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.28%
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
10
218
2160
0
6
218
2164
—
—
0
12
198
1972
—
Elevated level of transaminase and lactic acid dehydrogenase
274774002 [436238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
—
Astigmatism
H52.2 [45547934]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
0
7
218
2163
—
—
—
—
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
3.8e-01
2.8e-01
—
—
—
9.9e-03
5.0e-01
cases:22.48%
controls:16.54%
cases:9.17%
controls:7.10%
—
—
—
—
—
—
cases:7.07%
controls:7.01%
cases:22.06%
controls:14.64%
49
359
169
1811
20
154
198
2016
—
—
—
14
139
184
1845
30
191
106
1114
Ulcerative (chronic) rectosigmoiditis
K51.3 [45533603]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.23%
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
7
218
2163
0
6
218
2164
0
5
218
2165
—
—
0
5
198
1979
—
Cardiology
6 [38004451]
-1.4e-01
8.0e-01
—
—
—
5.8e-01
4.9e-01
cases:6.42%
controls:7.33%
cases:6.42%
controls:3.00%
—
—
—
—
—
—
cases:3.54%
controls:2.02%
cases:9.56%
controls:6.05%
14
159
204
2011
14
65
204
2105
—
—
—
7
40
191
1944
13
79
123
1226
Benign neoplasm: Skin of eyelid, including canthus
D23.1 [45600585]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Hypertrophy of nasal turbinates
J34.3 [45543264]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Olecranon bursitis
M70.2 [45557961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Hypertrophy of breast
N62 [45577538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Maternal care for (suspected) chromosomal abnormality in fetus
O35.1 [45606585]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
Basophils [#/volume] in Blood
26444-0 [3006315]
-2.1e-03
4.9e-01
5.5e-01
—
5.9e-01
3.6e-01
1.2e-01
cases:16.06%
controls:16.08%
cases:13.30%
controls:8.57%
cases:2.29%
controls:1.34%
—
—
cases:2.30%
controls:1.30%
cases:10.61%
controls:7.66%
cases:14.71%
controls:13.26%
35
349
183
1821
29
186
189
1984
5
29
213
2141
—
5
28
212
2132
21
152
177
1832
20
173
116
1132
Toothache NOS
K08.80 [2000502799]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.53%
—
—
—
—
—
—
5
20
131
1285
Contusion of finger(s) without damage to nail
S60.0 [45535417]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
phenoxymethylpenicillin; oral
J01CE02 [21602842]
4.3e-01
-1.5e-01
—
—
—
8.2e-01
6.3e-01
cases:18.35%
controls:12.72%
cases:2.75%
controls:3.18%
—
—
—
—
—
—
cases:7.58%
controls:3.48%
cases:19.85%
controls:11.65%
40
276
178
1894
6
69
212
2101
—
—
—
15
69
183
1915
27
152
109
1153
leflunomide; oral
L04AK01 [955035]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
198
1979
—
Mitral (valve) prolapse
I34.1 [45552788]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
7
218
2163
—
—
—
—
—
0
5
136
1300
SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
26975-3 [3025245]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
218
2152
—
—
—
—
—
—
Internal derangement of knee
M23 [45548358]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Glucose [Moles/volume] in Capillary blood
51596-5 [3040151]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
FXA00 [2001303347]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
mirtazapine; oral
N06AX11 [21604740]
2.9e-01
-1.0e-01
—
—
-1.0e+50
5.3e-01
5.6e-01
cases:9.17%
controls:7.00%
cases:3.67%
controls:4.06%
—
—
—
—
cases:0.00%
controls:0.97%
cases:4.55%
controls:2.72%
cases:9.56%
controls:5.67%
20
152
198
2018
8
88
210
2082
—
—
0
21
217
2139
9
54
189
1930
13
74
123
1231
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
7.9e-01
—
—
—
—
—
—
cases:3.67%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
—
—
8
37
210
2133
—
—
—
—
—
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1.6e-01
-3.2e-01
-1.0e+50
—
-1.0e+50
-2.8e-01
2.8e-01
cases:6.88%
controls:5.90%
cases:3.21%
controls:4.38%
cases:0.00%
controls:0.51%
—
—
cases:0.00%
controls:0.51%
cases:3.54%
controls:4.64%
cases:10.29%
controls:7.97%
15
128
203
2042
7
95
211
2075
0
11
218
2159
—
0
11
217
2149
7
92
191
1892
14
104
122
1201
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
4.3e-01
—
—
—
—
—
—
cases:3.21%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
7
46
211
2124
—
—
—
—
—
—
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
1.4e-01
—
—
—
—
—
9.0e-01
cases:2.75%
controls:2.40%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:1.84%
6
52
212
2118
—
—
—
—
—
6
24
130
1281
Physiotherapist
Z3226 [2001311560]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
27
218
2143
—
—
—
—
0
6
198
1978
—
enalapril; oral, parenteral
C09AA02 [21601786]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
0
12
217
2148
—
—
Acute stress reaction
F43.0 [45591139]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
11
218
2159
—
—
—
—
—
Spontaneous abortion, Incomplete, without complication
O03.4 [45558185]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
2.4e-01
—
—
—
—
—
—
cases:5.05%
controls:4.01%
—
—
—
—
—
—
—
—
—
—
—
—
11
87
207
2083
—
—
—
—
—
—
Basal cell carcinoma, NOS, of skin, NOS
8090/3-C44.9 [44505057]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
6
218
2164
—
—
—
—
—
0
6
136
1299
Acute vaginitis
N76.0 [45543891]
1.0e+00
1.6e+00
—
—
—
—
—
cases:4.59%
controls:1.71%
cases:2.29%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
10
37
208
2133
5
10
213
2160
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
8.3e-01
—
—
—
—
—
—
cases:2.29%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
5
22
213
2148
—
—
—
—
—
—
Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection
69002-4 [40771527]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
-2.3e-01
1.3e+00
—
—
—
—
—
cases:2.29%
controls:2.86%
cases:2.75%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
5
62
213
2108
6
16
212
2154
—
—
—
—
—
dexamethasone and antiinfectives
S02CA06 [21605178]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Contact with and exposure to unspecified communicable disease
Z20.9 [45595489]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.20%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
26
218
2144
0
5
218
2165
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
5.6e-01
—
—
—
—
-1.0e+50
—
cases:7.34%
controls:4.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
16
94
202
2076
—
—
—
—
0
8
198
1976
—
Preparation for dental prosthetics
SPA02 [2001310460]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
198
1979
—
Physiotherapy
R4110 [2001310233]
2.1e-01
—
—
—
—
—
—
cases:5.96%
controls:4.88%
—
—
—
—
—
—
—
—
—
—
—
—
13
106
205
2064
—
—
—
—
—
—
oxytetracycline
S01AA04 [21603557]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
fluticasone; inhalant
R03BA05 [21603288]
4.6e-01
—
—
—
-1.0e+50
—
—
cases:4.59%
controls:2.95%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
10
64
208
2106
—
—
—
0
5
217
2155
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
1.7e-01
2.8e-01
1.1e-01
—
6.6e-01
4.0e-01
1.7e-01
cases:37.61%
controls:33.78%
cases:26.61%
controls:21.43%
cases:4.59%
controls:4.15%
—
—
cases:5.99%
controls:3.19%
cases:28.28%
controls:20.97%
cases:37.50%
controls:33.72%
82
733
136
1437
58
465
160
1705
10
90
208
2080
—
13
69
204
2091
56
416
142
1568
51
440
85
865
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
—
rosuvastatin; oral
C10AA07 [21601862]
-3.9e-01
—
—
—
—
-2.5e-01
-4.1e-01
cases:3.21%
controls:4.65%
—
—
—
—
—
—
—
—
cases:3.54%
controls:4.49%
cases:4.41%
controls:6.51%
7
101
211
2069
—
—
—
—
7
89
191
1895
6
85
130
1220
Endomysium IgA Ab [Titer] in Serum
10863-9 [3020961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
0
22
136
1283
Other specified coagulation defects
D68.8 [45532994]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
—
—
—
—
—
—
7.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.62%
controls:3.30%
—
—
—
—
—
—
9
43
127
1262
Teaching
WZC30 [2001310891]
8.1e-02
—
—
—
—
—
—
cases:2.29%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
5
46
213
2124
—
—
—
—
—
—
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.53%
—
—
—
—
—
—
5
20
131
1285
Migraine
N89 [2002000789]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
0
10
198
1974
—
Crohn disease of large intestine
K50.1 [45601173]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.28%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
0
6
218
2164
0
7
218
2163
—
—
—
0
5
198
1979
—
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.00%
—
—
—
—
—
—
5
13
131
1292
Counselling, unspecified
Z71.9 [45561648]
7.8e-01
—
—
—
—
—
—
cases:2.29%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
213
2147
—
—
—
—
—
—
prednisone; oral
H02AB07 [21602735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
22
218
2148
—
—
—
—
—
—
Myalgia
M79.1 [45587062]
7.5e-01
—
—
—
—
—
8.2e-01
cases:5.96%
controls:2.90%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:1.99%
13
63
205
2107
—
—
—
—
—
6
26
130
1279
metoprolol; oral, parenteral
C07AB02 [21601684]
-6.4e-02
—
-1.0e+50
—
-1.0e+50
—
—
cases:2.29%
controls:2.44%
—
—
cases:0.00%
controls:0.55%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
5
53
213
2117
—
0
12
218
2158
—
0
7
217
2153
—
—
Brachial plexus disorders
G54.0 [45586302]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
218
2161
—
—
—
—
—
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Other psoriatic arthropathies
M07.3*L40.5 [2000503010]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
Low back symptom/complaint
L03 [2002000628]
3.7e-01
6.9e-01
—
—
—
2.1e-01
7.9e-01
cases:7.80%
controls:5.53%
cases:4.59%
controls:2.35%
—
—
—
—
—
—
cases:2.53%
controls:2.07%
cases:9.56%
controls:4.60%
17
120
201
2050
10
51
208
2119
—
—
—
5
41
193
1943
13
60
123
1245
azelastine; nasal
R01AC03 [21605035]
3.2e-01
1.9e-01
—
—
—
5.4e-01
7.7e-01
cases:9.17%
controls:6.82%
cases:5.05%
controls:4.19%
—
—
—
—
—
—
cases:6.06%
controls:3.63%
cases:11.76%
controls:5.82%
20
148
198
2022
11
91
207
2079
—
—
—
12
72
186
1912
16
76
120
1229
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.8e-01
4.0e-01
—
—
—
—
5.1e-01
cases:12.39%
controls:10.60%
cases:3.67%
controls:2.49%
—
—
—
—
—
—
—
—
cases:9.56%
controls:5.98%
27
230
191
1940
8
54
210
2116
—
—
—
—
13
78
123
1227
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.1e+00
—
—
—
—
—
—
cases:4.13%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
9
32
209
2138
—
—
—
—
—
—
Kolposcopy
ULA02 [2001306679]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.00%
—
0
8
218
2162
—
—
—
0
7
198
1977
0
13
136
1292
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
8.9e-01
—
—
—
—
—
—
cases:2.75%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
6
25
212
2145
—
—
—
—
—
—
dutasteride; oral
G04CB02 [21602676]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
198
1979
—
Psychiatric treatment plan, standard
ICB01 [2001304098]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.54%
—
—
—
—
—
0
10
198
1974
0
7
136
1298
Fluoride application or other respective small prophylactic procedure
SCC01 [2001310310]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Mitochondria Ab [Titer] in Serum
20483-4 [3034770]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
218
2151
—
—
—
—
—
—
General anesthesia, balanced
WX408 [2001310808]
4.8e-02
—
—
—
—
—
—
cases:2.75%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
—
—
6
57
212
2113
—
—
—
—
—
—
Systemic arterial pressure
364090009 [4238447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
218
2163
—
—
—
—
—
—
Diabetic background retinopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.00*E10.3 [2000503930]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
5
218
2165
—
—
—
—
—
0
5
136
1300
Extensive body CT
JN4BD [2001310899]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
218
2162
—
—
—
—
—
—
Hypersensitivity skin testing
268377001 [4147813]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
5
198
1979
—
Protein S Free Ag actual/normal in Platelet poor plasma by Immunoassay
27821-8 [3020629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
218
2160
—
—
—
—
—
—
Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum
16135-6 [3018658]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
Attention to surgical dressings and sutures
Z48.0 [45609943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
218
2161
—
—
—
—
—
—
Choriogonadotropin.beta subunit free [Moles/volume] in Serum or Plasma
2115-4 [3019497]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—
C reactive protein [Mass/volume] in Capillary blood
48421-2 [3051387]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
14
136
1291
Rectal/anal pain
D04 [2002000303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
218
2164
—
—
—
—
—
—
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
0
5
218
2165
—
—
—
—
0
6
136
1299
Elevated blood-pressure reading, without diagnosis of hypertension
R03.0 [45553712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
almotriptan; oral
N02CC05 [21604380]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
Synovitis and tenosynovitis
M65 [45533890]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
218
2165
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
112
787
1.72
4.45
3.6
2.2
—
—
—
0
0
116
849
1.64
3.81
4.3
4.0
58.06
83.18
e6/l
0.17
79
568
20
79
2.65
3.72
6.8
1.7
—
—
—
0
0
80
537
1.70
3.64
3.5
1.9
—
—
—
0
0
49
288
1.86
3.49
1.4
1.4
—
—
—
0
0
86
599
1.64
3.36
3.5
3.1
0.13
0.34
e6/l
2.16
65
441
96
696
1.59
3.16
3.5
3.2
12.04
46.21
e6/l
2.41
75
529
197
1685
1.63
3.12
8.1
8.1
73.08
78.02
u/l
1.40
182
1602
31
169
1.94
2.77
4.5
1.5
—
—
—
0
0
145
1179
1.50
2.71
6.2
6.6
12.42
13.07
umol/l
0.13
136
1122
78
562
1.55
2.57
1.7
1.5
21.71
20.23
nmol/l
0.42
69
487
41
251
1.75
2.56
1.4
1.4
—
—
—
0
0
37
221
1.78
2.51
2.6
4.8
2.78
1.62
mmol/l
0.64
31
185
31
177
1.85
2.43
5.0
1.5
—
—
—
0
0
34
201
1.79
2.39
4.8
9.3
—
—
—
0
0
60
414
1.58
2.37
2.7
1.7
—
—
—
0
0
31
179
1.83
2.35
5.3
1.5
—
—
—
0
0
67
477
1.54
2.31
3.1
2.6
6.68
7.65
e6/l
0.16
61
430
20
100
2.08
2.27
1.2
1.2
—
—
—
0
0
126
1023
1.43
2.24
2.5
2.7
69.22
72.84
nmol/l
0.89
115
940
82
1056
0.68
2.23
3.2
2.8
—
—
—
0
0
87
662
1.46
2.17
1.8
1.8
—
—
—
0
0
63
450
1.52
2.13
1.4
1.3
16.37
7.91
u/ml
0.55
29
186
30
177
1.78
2.13
5.2
1.5
—
—
—
0
0
18
89
2.10
2.11
2.9
5.1
126.33
404.58
mg/l
—
9
38
102
808
1.42
2.03
6.1
6.4
—
—
—
0
0
30
181
1.74
1.98
5.4
1.5
—
—
—
0
0
92
721
1.42
1.93
3.6
3.1
2.35
2.35
mmol/l
0.02
78
659
112
909
1.40
1.92
2.2
1.9
98.03
95.47
pmol/l
0.26
58
483
36
231
1.64
1.91
3.3
2.5
23.03
29.40
u/l
2.39
31
194
154
1322
1.38
1.86
5.1
5.1
6.39
6.46
mmol/l
0.15
140
1220
7
23
3.10
1.81
2.1
1.7
—
—
—
0
0
35
228
1.61
1.76
2.6
4.7
7.37
7.38
ph
0.21
15
145
8
30
2.72
1.74
3.0
2.2
16.70
16.60
%
—
8
30
138
1174
1.36
1.72
5.5
6.4
55.96
56.63
%
0.27
125
1137
65
490
1.43
1.67
1.4
1.3
19.49
28.09
iu/ml
0.53
15
146
31
199
1.63
1.66
2.9
2.2
11291.52
9272.97
u/l
0.10
17
79
6
20
3.04
1.59
6.8
1.4
—
—
—
0
0
41
285
1.52
1.58
4.6
3.3
4.97
6.95
umol/l
0.99
30
248
108
896
1.34
1.54
5.4
5.5
35.16
36.85
g/l
2.26
102
856
134
1149
1.33
1.53
5.9
6.6
2.80
2.76
%
0.07
120
1096
77
609
1.37
1.49
2.6
2.7
—
—
—
0
0
134
1154
1.32
1.46
6.0
6.6
8.13
8.53
%
1.10
120
1107
126
1077
1.32
1.44
4.0
3.2
6.31
6.20
ph
0.43
65
624
133
1147
1.31
1.43
6.0
6.6
0.68
0.68
%
0.05
118
1090
49
361
1.44
1.42
3.3
2.5
2.43
2.43
mmol/l
0.05
42
324
41
292
1.48
1.41
1.9
1.6
—
—
—
0
0
39
275
1.49
1.41
5.0
7.6
102.82
104.39
mmol/l
0.98
39
275
39
276
1.48
1.39
1.6
1.6
—
—
—
0
0
6
23
2.64
1.37
1.2
3.4
10.43
11.99
%
—
6
23
93
767
1.32
1.36
2.7
2.3
—
—
—
0
0
68
536
1.36
1.34
2.3
2.1
0.75
1.27
mg/l
1.78
48
405
6
24
2.53
1.31
1.5
1.1
—
—
—
0
0
13
69
1.93
1.31
2.4
1.7
0.82
0.38
nmol/l
0.31
13
61
148
1307
1.29
1.29
6.1
6.7
0.19
0.19
e9/l
0.10
121
1153
155
1379
1.29
1.26
8.3
9.9
4.06
4.05
e9/l
0.01
131
1213
29
201
1.50
1.16
5.0
3.1
—
—
—
0
0
46
349
1.38
1.15
2.7
3.0
4.15
2.27
e6/l
0.60
27
177
70
570
1.31
1.10
2.3
2.1
2.37
2.78
mg/l
1.16
58
503
141
1254
1.26
1.10
6.1
6.6
0.53
0.57
e9/l
1.00
117
1092
8
41
1.98
1.09
4.5
3.9
3.49
4.24
e9/l
—
8
41
5
21
2.41
1.09
1.6
1.3
—
—
—
0
0
53
418
1.33
1.04
3.5
2.6
546.24
537.17
mosm/kgh2o
0.08
45
364
134
1190
1.25
1.04
6.0
6.5
29.30
29.09
%
0.08
124
1150
5
22
2.30
1.04
1.2
1.1
—
—
—
0
0
42
320
1.37
1.03
2.1
2.1
—
—
—
0
0
127
1122
1.25
1.03
2.9
2.8
—
—
estimate
—
0
0
17
107
1.63
1.02
1.2
3.3
0.51
0.60
%
0.83
17
107
145
1301
1.25
1.02
4.3
3.4
0.00
0.00
estimate
-0.00
34
262
147
1322
1.25
1.01
4.3
3.5
0.00
0.00
estimate
-0.00
33
250
197
1834
1.27
0.99
5.5
4.6
14.25
14.56
pmol/l
1.08
182
1720
7
36
1.97
0.97
3.7
2.6
5.04
5.03
kpa
—
7
36
7
36
1.97
0.97
3.7
2.6
9.53
9.25
kpa
—
7
36
140
1257
1.24
0.96
6.2
6.6
0.04
0.04
e9/l
0.28
117
1091
24
168
1.47
0.93
4.9
9.4
25.75
24.64
mmol/l
0.49
24
168
13
79
1.68
0.89
2.1
2.2
—
—
—
0
0
145
1314
1.22
0.89
4.3
3.4
36.71
12.00
estimate
0.29
35
261
8
43
1.89
0.88
1.5
1.1
—
—
—
0
0
142
1285
1.22
0.88
6.2
6.5
2.04
1.96
e9/l
0.31
120
1144
6
30
2.02
0.87
2.5
2.0
28.53
41.27
%
—
6
30
69
579
1.26
0.86
3.4
2.9
330.28
331.81
umol/l
0.05
60
528
72
610
1.25
0.83
4.6
4.3
7.39
7.40
ph
0.23
50
424
36
279
1.33
0.81
1.7
1.6
1382.09
1172.18
nmol/l
0.69
27
219
10
58
1.75
0.80
3.6
2.7
7.42
7.42
ph
—
10
58
84
728
1.22
0.78
4.3
3.4
8.51
8.65
mmol/l
0.08
73
639
6
34
1.78
0.77
3.5
4.0
94.67
91.17
%
—
6
34
83
720
1.22
0.76
5.5
6.3
—
—
—
0
0
243
2347
1.35
0.75
16.4
13.6
20.79
21.69
mg/l
0.19
202
1906
81
703
1.22
0.74
2.9
2.8
52.74
56.33
u/l
0.60
72
662
99
879
1.20
0.72
12.6
9.5
1.14
1.15
inr
0.09
80
716
21
152
1.41
0.71
2.8
2.5
65.28
75.84
e9/l
1.39
12
103
5
26
1.94
0.71
1.2
1.2
56.00
37.81
nmol/l
—
5
20
38
304
1.29
0.70
1.6
1.6
852.91
941.68
mu/l
0.26
25
257
10
61
1.66
0.69
4.4
3.2
56.55
57.00
%
—
10
61
21
153
1.40
0.69
1.9
1.2
—
—
—
0
0
21
154
1.39
0.67
2.6
1.5
0.57
0.33
mg/l
0.71
12
68
123
1121
1.18
0.65
10.8
10.4
0.00
0.00
e9/l
0.98
94
909
237
2290
1.29
0.65
16.8
14.4
139.07
139.58
mmol/l
2.88
231
2248
13
187
0.68
0.63
1.5
2.0
6.36
6.20
ph
—
7
109
237
2292
1.28
0.63
17.0
14.6
3.95
3.94
mmol/l
0.10
231
2241
78
692
1.18
0.56
5.0
3.4
0.00
0.00
estimate
0.50
33
250
8
122
0.65
0.56
1.0
1.1
1.51
1.51
g/l
—
8
122
20
151
1.35
0.56
1.6
1.2
—
—
—
0
0
43
361
1.23
0.55
1.3
1.4
340.00
389.59
titre
—
10
73
17
125
1.38
0.55
1.2
1.4
—
—
—
0
0
33
270
1.25
0.53
1.9
2.6
12.95
14.31
nmol/l
0.38
27
257
14
100
1.42
0.53
1.6
2.0
206.21
236.14
pmol/l
0.53
14
93
9
63
1.44
0.53
1.4
2.0
—
—
—
0
0
11
75
1.49
0.51
1.0
1.2
8.81
0.64
u/ml
—
5
38
220
2270
0.83
0.51
5.2
5.1
2.79
2.79
mmol/l
0.00
203
2152
35
290
1.24
0.51
1.5
1.3
—
—
—
0
0
215
2071
1.19
0.51
5.8
5.5
37.84
38.28
mmol/mol
0.30
199
1972
19
145
1.33
0.50
2.1
1.9
—
—
—
0
0
110
1016
1.14
0.46
6.5
7.8
1.21
1.21
mmol/l
0.15
98
887
15
112
1.36
0.45
1.6
1.9
0.00
0.00
estimate
—
6
36
18
229
0.77
0.44
1.3
1.3
276.40
121.31
u/ml
—
6
83
5
32
1.57
0.42
1.2
1.6
—
—
—
0
0
5
32
1.57
0.42
1.2
1.6
—
—
—
0
0
5
32
1.57
0.42
1.2
1.6
—
—
—
0
0
5
32
1.57
0.42
1.2
1.6
—
—
—
0
0
11
79
1.41
0.41
1.0
1.2
2.37
1.58
u/ml
—
5
43
61
545
1.15
0.41
6.1
4.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
219
2250
0.86
0.40
4.5
4.7
4.63
4.68
mmol/l
0.33
204
2142
76
691
1.14
0.40
1.2
1.4
1.40
1.82
u/ml
0.18
12
184
222
2157
1.16
0.39
6.3
5.3
1.71
1.79
mu/l
0.62
211
2040
5
35
1.44
0.39
3.0
4.1
3.08
5.69
u/ml
—
5
35
221
2147
1.16
0.39
4.7
4.3
5.82
5.83
mmol/l
0.04
204
2017
44
385
1.17
0.38
1.8
1.6
479.26
34111233.33
pmol/l
0.50
38
343
20
161
1.26
0.38
1.3
1.1
—
—
—
0
0
37
320
1.18
0.37
1.8
2.9
9.64
7.60
e9/l
0.14
29
292
5
76
0.65
0.36
1.0
1.3
—
—
—
0
0
15
117
1.30
0.36
7.3
11.3
0.69
0.66
%
0.10
15
117
9
125
0.71
0.36
1.0
1.2
1.04
0.88
g/l
—
9
125
249
2446
1.23
0.36
12.2
10.9
27.52
27.53
u/l
0.00
244
2394
82
755
1.12
0.35
2.8
2.8
—
0.29
—
0
7
91
844
1.12
0.35
1.8
1.7
—
—
—
0
0
12
91
1.33
0.34
1.0
1.2
11.13
2.75
u/ml
—
5
49
96
894
1.11
0.34
2.1
1.9
—
—
—
0
0
70
763
0.89
0.34
3.6
2.7
0.00
0.02
estimate
0.68
30
212
82
758
1.12
0.33
3.7
3.2
41.37
29.69
ng/l
0.32
42
441
12
92
1.32
0.32
5.7
5.2
1.52
1.23
mg/l
0.74
12
82
219
2241
0.88
0.32
4.5
4.6
1.39
1.43
mmol/l
0.94
199
2123
34
297
1.17
0.31
1.4
1.4
—
—
—
0
0
7
99
0.70
0.31
1.6
1.6
—
—
—
0
0
15
121
1.25
0.29
7.3
11.1
1.63
1.44
%
0.26
15
121
8
67
1.20
0.26
2.4
1.8
—
—
—
0
0
62
572
1.11
0.26
4.6
3.3
1.02
1.02
kg/l
0.38
40
380
42
381
1.12
0.24
2.9
2.4
236.70
100.02
ug/g
0.63
33
301
14
115
1.23
0.24
1.9
1.2
—
—
—
0
0
13
106
1.24
0.23
1.2
1.2
—
—
—
0
0
50
459
1.11
0.23
1.9
1.6
—
—
—
0
0
5
40
1.25
0.22
5.4
2.5
10.92
7.74
pmol/l
—
5
40
14
116
1.22
0.22
1.2
2.4
15.11
25.96
u/ml
1.84
14
111
29
258
1.14
0.22
1.1
1.2
—
—
—
0
0
5
42
1.19
0.21
4.6
2.2
—
—
—
0
0
8
101
0.79
0.21
1.0
3.1
—
—
—
0
0
24
211
1.15
0.21
1.7
1.8
0.00
0.00
estimate
—
6
51
0
11
0.00
0.21
0.0
7.6
—
7.80
—
0
11
0
11
0.00
0.21
0.0
4.8
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
34.00
—
0
5
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
0.43
—
0
13
0
13
0.00
0.21
0.0
4.2
—
—
—
0
0
211
2148
0.92
0.19
3.8
3.9
1.36
1.29
mmol/l
0.53
189
2027
6
53
1.14
0.19
1.0
1.2
—
—
—
0
0
24
268
0.89
0.18
1.7
1.8
3.61
3.49
mmol/l
0.17
19
191
132
1277
1.07
0.18
3.8
3.2
141.75
90.59
ug/l
0.61
122
1230
59
627
0.92
0.18
4.7
4.1
15.32
9.38
mg/mmol
0.22
40
412
9
80
1.13
0.15
1.0
1.2
—
—
—
0
0
13
112
1.17
0.14
2.1
3.1
137.71
130.73
ng/l
0.04
13
101
42
393
1.08
0.14
3.8
3.5
427.00
292.99
ng/l
0.24
32
258
38
407
0.92
0.14
2.2
2.6
0.66
0.69
ug/l
0.09
20
208
8
98
0.81
0.14
4.9
4.4
—
—
—
0
0
22
199
1.11
0.14
6.2
9.0
7.41
7.42
ph
0.33
12
112
20
180
1.12
0.13
1.4
1.7
—
—
—
0
0
59
617
0.94
0.12
3.6
3.5
81.51
75.10
mg/l
0.04
40
418
12
105
1.15
0.11
6.4
9.0
16.47
16.28
%
0.07
12
100
22
202
1.10
0.11
6.2
8.8
5.45
5.06
kpa
1.52
22
193
22
202
1.10
0.11
6.2
8.8
12.59
12.95
kpa
0.10
22
194
97
998
0.96
0.10
4.3
3.1
0.00
0.02
estimate
0.68
29
222
19
174
1.10
0.09
6.7
9.7
123.74
121.31
g/l
0.18
19
169
5
46
1.09
0.09
6.4
4.2
4.14
3.90
mmol/l
—
5
46
247
2453
1.08
0.09
13.8
11.8
—
—
—
0
0
65
628
1.05
0.09
1.2
1.4
2.40
2.28
g/l
0.08
33
402
15
136
1.11
0.08
1.6
1.6
—
—
—
0
0
5
60
0.83
0.08
1.4
1.3
—
—
—
0
0
5
65
0.76
0.08
15.6
9.6
—
—
—
0
0
6
71
0.84
0.07
1.8
4.0
11.00
2768.69
u/ml
—
6
64
6
70
0.85
0.07
1.7
1.4
401.67
180.77
u/ml
—
6
39
19
177
1.08
0.07
1.6
1.4
—
—
—
0
0
9
104
0.86
0.06
5.6
7.3
26.77
24.28
mmol/l
—
9
99
26
272
0.95
0.05
1.2
1.2
—
—
—
0
0
14
130
1.08
0.04
1.6
1.5
1.24
1.25
mm
—
6
97
11
119
0.92
0.04
7.9
5.5
—
—
—
0
0
61
622
0.98
0.03
5.3
4.7
—
—
—
0
0
14
132
1.06
0.02
1.6
1.6
—
—
—
0
0
177
1759
1.02
0.02
3.9
3.5
38.51
44.34
u/l
0.80
166
1698
96
969
0.99
0.01
1.7
1.9
1.72
1.40
mmol/l
1.20
87
843
17
177
0.96
0.01
6.7
9.6
96.72
95.58
%
0.57
17
172
260
2598
1.02
0.00
23.5
20.6
6.89
6.77
e9/l
0.44
253
2550
14
138
1.02
0.00
1.1
1.1
—
—
—
0
0
260
2599
1.01
0.00
23.6
20.6
136.50
137.39
g/l
0.45
260
2581
260
2597
1.03
0.00
23.4
20.4
30.12
30.18
pg
0.20
260
2578
260
2597
1.03
0.00
23.7
20.9
40.96
40.95
%
0.01
260
2576
260
2597
1.03
0.00
23.4
20.5
4.56
4.58
e12/l
0.31
255
2551
260
2595
1.05
0.00
23.4
20.5
256.21
255.80
e9/l
0.04
254
2556
65
646
1.01
0.00
3.5
4.0
1.49
1.59
ug/l
0.15
58
589
260
2596
1.04
0.00
23.4
20.5
90.18
90.19
fl
0.01
260
2578
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
5
54
0.92
0.00
1.2
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
148.51
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
0.02
—
0
5
6
62
0.97
-0.00
1.7
1.4
23.17
13.06
e6/l
—
6
49
8
85
0.94
-0.00
1.4
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
64.00
—
0
6
7
74
0.94
-0.00
1.0
1.3
—
95.00
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
63
0.95
-0.00
1.7
1.5
1398.83
121.47
e6/l
—
6
53
8
85
0.94
-0.00
1.4
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
10.96
—
0
9
0
5
0.00
-0.00
0.0
1.2
—
2.02
—
0
5
0
9
0.00
-0.00
0.0
1.6
—
60.22
—
0
9
8
79
1.01
-0.00
1.6
1.7
1.03
1.40
g/l
—
8
72
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.0
—
4.80
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
79.14
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
3.29
—
0
7
5
57
0.87
-0.00
1.2
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
55.92
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_PEDICULOSIS_AND_PHTHIRIAASIS_WIDE – Pediculosis and phthiriasis, including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).